Korsana Biosciences, Inc. (KRSA) Stock Forecast
KRSA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $44.00 average of analyst targets
- Upside to target
- +35.9% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.78
- 52-week range
- $7.56 – $44.66
KRSA analyst ratings
5 analystsNumber of analysts at each rating.
KRSA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KRSA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next quarter (Sep '26) | −$0.67 | −$0.67 | −$0.67 | — | — | 1 |
| Current fiscal year (2026) | −$1.70 | −$1.70 | −$1.70 | — | — | 1 |
| Next fiscal year (2027) | −$3.56 | −$3.56 | −$3.56 | −$1.70 | −108.9% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KRSA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Sep '26) | $0 | $0 | $0 | — | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
KRSA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KRSA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next quarter (Sep '26) | $0.00 | $0.00 | $0.00 | $0.00 | −$0.67 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | $0.00 | $0.00 | −$1.70 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | $0.00 | −$3.56 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KRSA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; KRSA beat in 1 of 1.
What analysts expect from KRSA
5 analysts cover Korsana Biosciences; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $44.00, 35.9% above the latest close of $32.38. Analysts expect earnings of −$1.70 per share for 2026. For 2027 the average estimate is −$3.56 per share. Korsana Biosciences beat the EPS estimate in 1 of the last 1 quarters.
Related: KRSA income statement, KRSA key metrics, KRSA chart. See the KRSA stock overview for the latest quote and news.
KRSA forecast FAQ
What is Korsana Biosciences's price target?
The average analyst price target for Korsana Biosciences is $44.00, 35.9% above the latest close of $32.38.
Is Korsana Biosciences a buy, hold or sell?
Of 5 analysts covering Korsana Biosciences, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Korsana Biosciences's EPS forecast?
Analysts forecast −$1.70 per share for 2026 (range −$1.70 to −$1.70); for 2027 the estimate is −$3.56.
When does Korsana Biosciences report earnings?
Korsana Biosciences is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.78.
Does Korsana Biosciences usually beat earnings estimates?
Korsana Biosciences reported EPS at or above the analyst estimate in 1 of the last 1 quarters.